Flow cytometric measurement of mitochondrial mass and function: A novel method for assessing chemoresistance

Annals of Surgical Oncology

Volumn 5, Issue 3, 1998, Pages 287-295

  Mancini, Mariangela ^a,b   Sedghinasab, Monireh ^a,b   Knowlton, Katya ^a,b   Tam, Amy ^b   Hockenbery, David ^b   Anderson, Benjamin O ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Apoptosis; Bcl 2 gene; Breast cancer; Chemoresistance; Mitochondria; Reactive oxygen species

Indexed keywords

ANTINEOPLASTIC AGENT; DNA FRAGMENT; HERBIMYCIN A; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE; CELL VIABILITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; LACTAMS, MACROCYCLIC; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINONES; REACTIVE OXYGEN SPECIES; REPRODUCIBILITY OF RESULTS; S PHASE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0031864290     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303787     Document Type: Article

References (47)

1. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992;52:2127-37.
2. Osborne CK, Clark GM, Ravdin PM. Treatment of early-stage breast cancer: adjuvant systemic therapy of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, eds. Diseases of the Breast. Philadelphia: Lippincott-Raven, 1996:548-78.
3. Allred DC, Clark GM, Tandon AK, et al. HER-2/Neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
4. Muss HB, Thor AD, Berry DA, et al. c-erb-2 expression and response to adjuvant therapy in women with node-positive breast cancer. N Engl J Med 1994; 330:1260-6.
5. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
6. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88:1308-14.
7. Geier A, Bar-Shalom I, Beery R, et al. Induction of apoptosis in MDA-231 cells by protein synthesis inhibitors is suppressed by multiple agents. Cancer Invest 1996;14:435-44.
8. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death. Br J Cancer 1991; 64:192-6.
9. Fisher DE, Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
10. Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anti-Cancer Drugs 1995;6:443-50.
11. Gregoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, Hittelman WN. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994;54:6201-9.
12. Potten CS. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metastasis Rev 1992; 11:179-95.
13. Moreira LF, Naomoto Y, Hamada M, Kamikawa Y, Orita K. Assessment of apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and radiotherapy. Anticancer Research 1995;15:639-44.
14. Omura S, Iwai Y, Takahashi Y, Sadakane N, Nakagawa A. Herbimycin, a new antibiotic produced by a strain of streptomyces. J Antibiot 1979;32:255-61.
15. Uehara Y, Hori M, Tackeuchi T, Umezawa H. Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology' : identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn J Cancer Res 1985;76:672-5.
16. Uehara Y, Hori M, Takeuchi T, Umezawa H. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 1986;6:2198-2206.
17. Murukami Y, Mizuno S, Hori M, Uehara Y. Reversal of transformed phenotypes by herbimycin A in src oncogene expressed rat fibroblasts. Cancer Res 1988;48:1587-90
18. Uehara Y, Murakami Y, Sugimoto Y, Mizuno S. Mechanism of reversion of Rous sarcoma virus transformation by Herbimycin A: reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60vsrc-1. Cancer Res 1989;49: 780-5.
19. Uehara Y, Murukami Y, Mizuno S, Kawai S. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology 1988;164:294-8.
20. Honma Y, Okabe-Kado J, Hozumi M, Uehara Y, Mizuno S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res 1989;49:331-4.
21. Mancini M, Paty PB, Hockenbery D, Lieberman MD, Anderson BO. Apoptosis (programmed cell death) is induced with differentiation and growth arrest in a human colon cancer by a Bcl-2 independent mechanism. Surg Forum 1995;46:507-9.
22. Mancini M, Anderson BO, Caldwell L, Sedghinasab M, Paty P, Hockenbery D. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol 1997;138:449-69.
23. Sambrook J, Fritsch EF, Maniatis T. Expression of cloned genes in cultured mammalian cells. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:16.39-16.40.
24. Reers M, Smith TW, Chen LB. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 1991;30:4480-6.
25. Smiley ST, Reers M, Mottola-Hartson C, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991;88:3671-5.
26. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative products formulation by neutrophils: a graded response to membrane stimulation. J Immunol 1983;130:1910-7.
27. Rothe G, Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with Hydroethidine and 2′,7′-dichlorofluorescein. J Leukocyte Biol 1990;47:440-8.
28. Hockenbery DM, Oltvai ZN, Yin X, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-51.
29. Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995; 182:367-77.
30. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 1956;62:315-23.
31. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
32. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
33. Henkart PA, Grinstein S. Apoptosis: mitochondria resurrected? J Exp Med 1996;183:1293-5.
34. Petit PX, O'Connor JE, Grunwald D, Brown SC. Analysis of the membrane potential of rat- and mouse-liver mitochondria by flow cytometry and possible applications. Eur J Biochem 1990;194: 389-97.
35. Vayssicre JL, Petit PX, Risler Y, Mignotte B. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc Natl Acad Sci USA 1994;91:11752-6.
36. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon M-I., Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 1995;130:157-67.
37. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere J-L, Petit PX. Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995;181:1661-72.
38. Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M, Kroemer G. Mitochondrial control of nuclear apoptosis. J Exp Med 1996;183:1533-44.
39. Marchetti P, Susin SA, Decaudin D, et al. Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res 1996;56:2033-8.
40. Reipert S, Berry J, Hughes MF, Hickman JA, Allen TD. Changes of mitochondrial mass in the hemopoietic stem cell line FDCP-mix after treatment with etoposide: a correlative study by multiparameter flow cytometry and confocal and electron microscopy. Exp Cell Res 1995;221:281-8.
41. Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994;15:7-10.
42. Peled-Kamar M, Lotem J, Okon E, Sachs L, Groner Y. Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: implications for Down syndrome. EMBO J 1995;14: 4985-93.
43. Busciglio J, Jankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995;378:776-9.
44. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the Bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res 1993;53:4701-14.
45. Riparbelli MG, Callaini G, Tripodi SA, Cintorino M, Tosi P, Dallai R. Localization of the Bcl-2 protein to the outer mitochondrial membrane by electron microscopy. Exp Cell Res 1995;221:363-9.
46. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection of thymocytes. Cell 1991;67:879-88.
47. Kane DJ, Serafian TA, Anton TA, et al. Bcl-2 inhibition of neuronal death: decreased generation of reactive oxygen species. Science 1993;262:1274-7.